Columnists
Tipsheet
Cartoons
Podcasts
Newsletters
Sections
Podcasts
Townhall TV
Election
Capitol Voices
Entertainment
Radio News
Live Blog
Topics
Sites
Hot Air
PJ Media
Bearing Arms
Twitchy
RedState
JOIN VIP
LOGIN
MY ACCOUNT
Account Settings
Newsletter Subscriptions
Log Out
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Acrivon Therapeutics, Inc. - Common Stock
(NQ:
ACRV
)
8.460
-0.010 (-0.12%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Apr 26, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
276,495
Open
8.530
Bid (Size)
8.200 (1)
Ask (Size)
8.600 (3)
Prev. Close
8.470
Today's Range
8.200 - 8.779
52wk Range
3.190 - 14.30
Shares Outstanding
N/A
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
April 25, 2024
Pre-market stock movers are a great way to start Thursday as we check out all of the hottest news moving shares this morning!
Via
InvestorPlace
12 Health Care Stocks Moving In Wednesday's After-Market Session
April 24, 2024
Via
Benzinga
Performance
YTD
+68.86%
+68.86%
1 Month
+30.86%
+30.86%
3 Month
+121.47%
+121.47%
6 Month
+68.53%
+68.53%
1 Year
-31.22%
-31.22%
More News
Read More
Acrivon Therapeutics Reports Initial Positive Clinical Data for ACR-368 and Pipeline Program Progress Today at Corporate R&D Event
April 24, 2024
From
Acrivon Therapeutics, Inc
Via
GlobeNewswire
Acrivon Therapeutics: Q4 Earnings Insights
March 28, 2024
Via
Benzinga
Acrivon Therapeutics to Host Corporate R&D Event Highlighting AP3 and Pipeline Progress, Including Ongoing Prospective Validation of ACR-368 OncoSignature with Initial Phase 2 Data for ACR-368, and Preclinical Progress for ACR-2316
April 16, 2024
From
Acrivon Therapeutics, Inc
Via
GlobeNewswire
Acrivon Therapeutics Presents Data at AACR Annual Meeting Highlighting the Capabilities of Acrivon Predictive Precision Proteomics (AP3) for the Discovery of ACR-2316, a Novel, Selective WEE1/PKMYT1 Inhibitor, and the Identification of Actionable
April 10, 2024
From
Acrivon Therapeutics, Inc
Via
GlobeNewswire
Crude Oil Down Over 1%; Cognyte Software Shares Plummet
April 09, 2024
Via
Benzinga
Topics
Stocks
Exposures
Fossil Fuels
US Equities
Why Tilray Brands Shares Are Trading Lower By Around 22%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
April 09, 2024
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
April 09, 2024
Via
Benzinga
Dow Dips 150 Points; Laser Photonics Shares Spike Higher
April 09, 2024
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Why Is Rail Vision (RVSN) Stock Up 17% Today?
April 09, 2024
Via
InvestorPlace
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
ACRV Stock Jumps 55% as Acrivon Therapeutics Gets $130 Million Boost
April 09, 2024
Via
InvestorPlace
Acrivon Therapeutics Stock Is Soaring Tuesday: What's Going On?
April 09, 2024
Via
Benzinga
Dow Gains Over 50 Points; Neogen Posts Downbeat Earnings
April 09, 2024
Via
Benzinga
Topics
Stocks
Exposures
US Equities
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
April 09, 2024
Via
Benzinga
Acrivon Therapeutics Announces $130 Million Private Placement Financing
April 09, 2024
From
Acrivon Therapeutics, Inc
Via
GlobeNewswire
ACRV Stock Earnings: Acrivon Therapeutics Misses EPS for Q4 2023
March 28, 2024
Via
InvestorPlace
Acrivon Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights
March 28, 2024
From
Acrivon Therapeutics, Inc
Via
GlobeNewswire
12 Health Care Stocks Moving In Friday's Intraday Session
March 15, 2024
Via
Benzinga
Acrivon Therapeutics to Present Data at AACR Annual Meeting Demonstrating Power of Acrivon Predictive Precision Proteomics (AP3) Platform and its Internally-Discovered, Potent WEE1/PKMYT1 Development Candidate, ACR-2316
March 05, 2024
From
Acrivon Therapeutics, Inc
Via
GlobeNewswire
Acrivon Therapeutics Appoints Santhosh Palani, Ph.D., CFA, Experienced Board Member and Healthcare Investor, to its Board of Directors
March 04, 2024
From
Acrivon Therapeutics, Inc
Via
GlobeNewswire
Acrivon Therapeutics to Participate in a Panel Discussion at the TD Cowen 44th Annual Health Care Conference
February 27, 2024
From
Acrivon Therapeutics, Inc
Via
GlobeNewswire
Acrivon Therapeutics Appoints Seasoned Industry Executive Ivana Magovčević-Liebisch, Ph.D., J.D., to Board of Directors
February 08, 2024
From
Acrivon Therapeutics, Inc
Via
GlobeNewswire
Acrivon Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
February 06, 2024
From
Acrivon Therapeutics, Inc
Via
GlobeNewswire
Acrivon Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
January 12, 2024
From
Acrivon Therapeutics, Inc
Via
GlobeNewswire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.